GLTO Profile
Galecto, Inc., a clinical-stage biotechnology firm, focuses on the development of novel therapeutic molecules targeting a range of diseases including fibrosis, cancer, and inflammation. The company is advancing a portfolio of innovative drug candidates designed to address significant unmet medical needs in these areas.
The company’s lead product candidate, GB2064, is currently in Phase IIa clinical trials for the treatment of myelofibrosis, a serious bone marrow disorder that leads to scarring of the bone marrow and severe anemia. This investigational therapy aims to offer new treatment options for patients with this challenging condition.
Additionally, Galecto is developing GB0139, an inhaled inhibitor of galectin-3 that is undergoing Phase IIb clinical trials. This drug candidate targets severe fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF), a progressive and life-threatening lung disease characterized by scarring of lung tissue. GB0139 represents a promising approach to treating IPF and other severe fibrotic conditions.
Another key product in Galecto’s pipeline is GB1211, a selective oral galectin-3 inhibitor. GB1211 is in Phase IIa trials for cancer treatment and Phase Ib/IIa trials for fibrosis. The compound aims to address both oncological and fibrotic conditions by targeting galectin-3, a protein involved in disease progression. Founded in 2011 and headquartered in Boston, Massachusetts, Galecto, Inc. is committed to advancing its innovative therapies through clinical development to provide effective treatments for serious diseases.
|
